In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquin...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreani, Julien, Le Bideau, Marion, Duflot, Isabelle, Jardot, Priscilla, Rolland, Clara, Boxberger, Manon, Wurtz, Nathalie, Rolain, Jean-Marc, Colson, Philippe, La Scola, Bernard, Raoult, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182748/
https://www.ncbi.nlm.nih.gov/pubmed/32344177
http://dx.doi.org/10.1016/j.micpath.2020.104228
Descripción
Sumario:Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.

Ejemplares similares